Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses

Long‐term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS). However, predictors of adherence are not well understood; past studies lacked lifestyle factors such as alcohol use and predictors of missed doses have not been evaluated. We examined both levels of non‐adherence—stopping IMD and missing doses.

[1]  R. Snaith,et al.  The hospital anxiety and depression scale. , 2013, Acta psychiatrica Scandinavica.

[2]  M. Mura,et al.  Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. , 2006, Functional neurology.

[3]  Ross T Tsuyuki,et al.  A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.

[4]  D. Paty,et al.  Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.

[5]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[6]  X. Montalban,et al.  Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis , 2005, Multiple sclerosis.

[7]  A J Thompson,et al.  Multiple sclerosis: diagnosis and the management of acute relapses , 2005, Postgraduate Medical Journal.

[8]  M Hutchinson,et al.  Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns , 2005, Multiple sclerosis.

[9]  B. Bergamasco,et al.  High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study , 2004, Journal of the Neurological Sciences.

[10]  V. Martinelli,et al.  A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients , 2003, Journal of neurology, neurosurgery, and psychiatry.

[11]  L. Munari,et al.  Therapy with glatiramer acetate for multiple sclerosis. , 2003, The Cochrane database of systematic reviews.

[12]  H. Tremlett,et al.  Interrupted therapy , 2003, Neurology.

[13]  R Brian Haynes,et al.  Helping patients follow prescribed treatment: clinical applications. , 2002, JAMA.

[14]  D. Goodin,et al.  Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.

[15]  L. Kappos,et al.  A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS , 2002, Neurology.

[16]  A. Ghezzi,et al.  Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.

[17]  T. T. Haug,et al.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.

[18]  L. Munari,et al.  Interferon in relapsing-remitting multiple sclerosis. , 2001, The Cochrane database of systematic reviews.

[19]  E. Vermeire,et al.  Patient adherence to treatment: three decades of research. A comprehensive review , 2001, Journal of clinical pharmacy and therapeutics.

[20]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[21]  B. Bergamasco,et al.  Interferon-β dose and efficacy: the OPTIMS study , 2001, Neurological Sciences.

[22]  D. Goodkin,et al.  Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la , 1998, Multiple sclerosis.

[23]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[24]  T. Perneger.  What's wrong with Bonferroni adjustments , 1998, BMJ.

[25]  D. Mohr,et al.  Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. , 1997, Archives of neurology.

[26]  D. Mohr,et al.  Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment , 1996, Multiple sclerosis.

[27]  R. Haynes,et al.  Is this patient taking the treatment as prescribed , 1993 .

[28]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[29]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.

[30]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[31]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[32]  R B Haynes,et al.  Predicting compliance with a regimen of digoxin therapy in family practice. , 1980, Canadian Medical Association journal.

[33]  Hayden B. Bosworth,et al.  Patient Treatment Adherence : Concepts, Interventions, and Measurement , 2008 .

[34]  T. Tombaugh,et al.  A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). , 2006, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[35]  B. Bergamasco,et al.  Interferon-beta dose and efficacy: the OPTIMS study. , 2001, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[36]  Hristian,et al.  RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .

[37]  R. Haynes,et al.  The rational clinical examination. Is this patient taking the treatment as prescribed? , 1993, JAMA.

[38]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.